posted
Hey Guys this may be worth looking into. Volume high and news just out at noon. Caption below
SHENZHEN, China, July 10 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com - announced today that the second batch of Hepatitis A Vaccine of 2009 was delivered to India, by the company.
This is the second completed batch exported to India this year by the company. The first batch was delivered to India in March.
posted
HIGH VOLUME TODAY * 477m; closed * .0011, near 52 week low
Hard To Treat Diseases (HTDS.PK) Agreement With 2nd Largest Vaccine Manufacturer in China Yunnan Walvax Biotech Co
SHENZHEN, China, July 13 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com - subsidiary, Mellow Hope signed an agreement with Yunnan Walvax Biotech Co., Ltd for the Haemophilus influenza type b conjugate vaccine. Yunnan Walvax Biotech Co. Ltd is the second biggest manufacturer of Haemophilus influenza type b conjugate vaccine in China. This agreement / arrangement now sets the stage for Mellow Hope to be fully authorized to conduct the international marketing of Haemophilus influenza type b conjugate vaccine in the global market.
In other corporate news, the company plans on commencing the registration in Chile, Indonesia, Egypt, and Russia within this month with the brand name 'MEVAC-Hib'.
The company will provide further details as they become available.
-------------------- Only ONE good stock away from retirement! Posts: 493 | Registered: May 2009
| IP: Logged |
posted
Could make a move. Always do your own research.
Hard To Treat Diseases (HTDS.PK) Tender Order To Indonesia 12 minutes ago - Pr Newswire
HTDS 0.0012 9.09%
As of 1:29 PM ET 7/15/09 Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com announced today that the company is now preparing for the tender business of 250,000 doses of MEVAC-ACYW in Indonesia.
This is the second completed batch exported to Indonesia this year by the company. The first batch was delivered to Indonesia in December 2008. At that time, the company successfully exported 70,000 doses of the product to Indonesia. Mr. Terry Yan CEO of HTDS said "The positive feedback of our product will help us to win the tender again this year. Our European division Slavica Bio Chem continues with its research and we are hopeful to release some further details of their work shortly."
Posts: 406 | From: San Diego | Registered: Jun 2009
| IP: Logged |
Hard to Treat Diseases, Inc. (HTDS) Reports on Ribavirin Research as Potential Treatment for MS
BELGRADE, SERBIA, July 23 /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS:PK) http://www.htdsmedical.com reports that researchers in its Slavica BioChem division have advised of some significant findings regarding its research into the use of Ribavirin in the treatment of Multiple sclerosis (MS).
The research team has been conducting experiments using Dark Agouti rats. Experimental autoimmune encephalomyelitis (EAE) induced in susceptible strains of animals provides the best available model for studying events in MS and a helpful tool in preclinical testing of various substances considered for treatment of the central nervous system (CNS) disease. CNS is the part of the nervous system that functions to coordinate the activity of all parts of the bodies of multicellular organisms.
In summary, these findings suggest that Ribavirin attenuates experimental autoimmune encephalomyelitis (animal model of multiple sclerosis) by limiting cytokine-mediated immuno-inflammatory events that lead to CNS destruction.
The conducted experiments provide rationale for ribavirin to be considered as a candidate drug in the development of new therapeutic strategies for the treatment of autoimmune diseases in humans, such as multiple sclerosis. One of the benefits of working with established drugs such as ribavirin, which has been in use approximately twenty years, is that the significant experience and history of the drug make it easier to obtain approval for use in new applications, such as the research that has been conducted by Slavica BioChem.
-------------------- Only ONE good stock away from retirement! Posts: 493 | Registered: May 2009
| IP: Logged |
posted
Hard to Treat Diseases (HTDS) To Re Release European TV Segment In N. America For Potential Treatment Of MS
BELGRADE, SERBIA, July 28 /PRNewswire-FirstCall/ -- Hard to Treat Diseases, Inc. (HTDS:PK) http://www.htdsmedical.com/, Slavica Bio Chem Division (Slavica) intends to re release a TV feature on the work of the medical team in the area of potential treatment of MS. The TV feature was aired in Europe only, several years ago.
Dr. Sanja Pekovic, Chief Project Scientist, Chief Strategy Officer explains: "A few years ago Serbian government TV did a feature about our work, and it took a great public attention. It was about Multiple sclerosis, current therapies, there were also some patients, and our whole team. All of us were talking about our work, our results, our lab was also presented. Also, there were some short movies about MS. It was very good and they repeated it several times on TV." Currently the company is in the process of obtaining translations and writing to the Director of RTS (TV) and intends to post the interview on its corporate web sites http://www.slavicabiotech.com/ and http://www.htdsmedical.com/. The company intends to make use of other media ie CD/DVD and similar to distribute the content to other medical professionals, research organizations, and companies in the medical industry to shed additional spotlight on the work of the Slavica Bio Tech team.
In other company news, within the next few weeks Slavica Bio Tech division intends to conduct a web cast only to address the work of Slavica. Dr.Sanja Pekovic, added: "Considering the potential, the exposure, and the spotlight this interview may bring to the company we are grateful and it is our pleasure, to have Professor Rakic (See Biography Link) (http://www.sanu.ac.rs/English/Clanstvo/Biografije/LjubisavRakic.pdf ) accept our invitation to be Slavica's spokesperson for the web cast. He is our Chief scientist and Ribavirin was his idea at the start. Professor Rakic is a well known and highly regarded and respected scientist. He is also the Vice-President of the Serbian Academy of Sciences and Arts in charge for natural sciences."
Company followers are advised that a similar and a second web cast is being planned to feature only the Mellow Hope (HTDS China Subsidiary Vaccine Division) http://www.mellowhope.com/en/main.asp. This second webcast will be chaired by the HTDS CEO, Mr. Terry Yuan.
Dr Pekovic concluded: "We are eager to get the message out to the industry on the work that our team is doing at Slavica. By that we mean not only to our shareholders but to the medical industry as well. We believe that our work is invaluable, that we have made some significant strides, which simply cannot be ignored and we believe that the market is just starting to take notice of our potential. To that end we have hired a liaison contact person, Dr. Ivana Gadjanski. Ivana comes highly qualified to us. She is a PhD. She has recently returned from Germany where she finished her PhD studies and got her PhD diploma, and now is a part of our team. Also, she is an assistant professor at the State University Novi Pazar, she speaks: English -professionally, CAE certificate, grades A, German - upper intermediate level, French - basics and is an enthusiastic young scientist with a lot of fresh and original ideas.
In our team she is responsible for introducing stem cell therapy in our models of EAE/MS and traumatic brain injury. Her duties will also include sending regular updates of our work to our North American office, the head office in China, and having our North American office and our advisors disseminate timely updates to the HTDS followers, shareholders and the medical professionals."
The company intends to provide many updates on the work and HTDS activities on a timely basis.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT:
CONTACT:
DATASOURCE: Hard to Treat Diseases
CONTACT:
-------------------- Please buy responsibly. Do not take my word on any stock. Do your own research. Thanks & good luck! Posts: 439 | From: USA | Registered: Jul 2009
| IP: Logged |
posted
Hard to Treat Diseases, Inc. (HTDS) TO Appoint Prof Mirjana Stojiljkovic As A Medical Advisor - Company Officer
BELGRADE, SERBIA, July 29 /PRNewswire-FirstCall/ -- Hard to Treat Diseases, Inc. (HTDS:PK), http://www.htdsmedical.com/ announced today that it will shortly appoint Prof Mirjana Stojiljkovic as a Medical Advisor to HTDS.
Prof Mirjana Stojiljkovic is a well respected scientist. Prof Stojiljkovic leads a group of researchers from Department of Neurobiology, Institute for Biological Research "Sinisa Stankovic", University of Belgrade, Serbia, (IBISS group). The group introduced a novel therapeutic approach in treatment of multiple sclerosis (MS), a severe, currently incurable, human disease. The effectiveness of this therapy is shown in experimental animals and has to be proven in people with MS, so that obtained results has to be considered as "experimental." Experimental data obtained on laboratory animals provide the following beneficial effects of the therapy:
- The severity of clinical signs of disease was significantly reduced - The pathological changes in the myelin sheath (demyelination) were not detected - The reduction of mononuclear cell infiltrates, composed of T cells and macrophages/microglia was observed in the spinal cord tissue - The degree of disability was lowered - The duration of the disease was notably shortened - The percentage mortality in severe disease was radically reduced (70%) - The severity of treatment side effects was low and disappeared after cessation of drug application
The appointment will effectively take place after the review of the current Adequate Disclosure filed with Pink Sheets, and will be reflected in the issuer's next quarterly Adequate Disclosure filing update. The issuer has heard back from Pink Sheets on its original Adequate Disclosure submission. The company's barrister is currently complying with the requests made by the Pink Sheets review staff. The company expects to be in full compliance and to obtain the highest tier ranking of Pink Sheets with the "Current Information" ranking. See: http://www.pinksheets.com/pink/otcguide/investors_market_tiers.jsp shortly.
Dr. Sanja Pekovic, Chief Project Scientist, Chief Strategy Officer of HTDS said "The appointment of Prof Mirjana Stojiljkovic to HTDS will be a great asset to our whole organization. We have requested to meet our corporate advisors here in Belgrade in mid August, and representatives of Mellow Hope http://www.mellowhope.com/ (Mellow Hope is a China based second operating subsidiary of HTDS in the business of vaccine distribution) to amongst other things discuss appointments and expanded role of other medical professionals to the HTDS board. We will also start working on a new web site for Slavica Bio Chem and HTDS Medical as well. On the operational updates and something we will do from time to time to keep our followers advised of our progress, and just to keep in touch; our newest young scientist Dr. Ivana Gadjanski, Communication Director Chief Liaison who just joined our team will attend the The International Summer School, Piran, Slovenia, August 21 - 29, 2009 on stem cells and regenerative medicine.
The International Summer School, Piran, Slovenia, August 21 - 29, 2009 is a PhD-level course for graduate students in life sciences focusing on advanced approaches to isolation, characterization and differentiation of stem cells. The aim is to introduce the students to different aspects of stem cell research and development of new strategies for their clinical applications. The course is covering a wide range of topics, starting with the problem of selection of stem cell source, ethical and legislative issues, followed by laboratory scale systems and engineering, and ending with translation to clinics."
The company invites any inquiries from qualified medical professionals to contact Dr. Ivana Gadjanski, , regarding the MS and CNS progress and reports.
The company intends to provide further updates shortly, and a brief CEO statement from Mr Terry Yuan, HTDS CEO, and which will include the issuers forward guidance.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact ; For any corporate matters, please contact , http://www.htdsmedical.com/
DATASOURCE: Hard to Treat Diseases
CONTACT: For medical and scientific dialogue inquiry only, please
contact ; For any corporate matters, please contact
-------------------- Please buy responsibly. Do not take my word on any stock. Do your own research. Thanks & good luck! Posts: 439 | From: USA | Registered: Jul 2009
| IP: Logged |
posted
Hard to Treat Diseases, Inc. (HTDS) Thai Registration Dossier
SHENZHEN, China, July 31 /PRNewswire-FirstCall/ -- Hard to Treat Diseases, Inc. (HTDS:PK), http://www.htdsmedical.com/ announced today that its registration dossier for MEVAC-DTaP (Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine, adsorbed) had passed the preliminary consideration of the experts in Thai FDA. The sample analysis is expected to be completed within the next 30 days.
Mr. Terry Yuan CEO of HTDS said (sic) "We welcome the expanded role of the medical team in Serbia. There has been a great synergy between the medical group in Serbia and us here in China, right from day one. I have great admiration for the work they are doing which is simply amazing. It is our goal and target to see the fruits of our labour begin to pay off for us and all of our shareholders.
HTDS was a company acquired by the new management, with the backing of our financiers' under duress, just less than a year ago. Many of HTDS long time shareholders basically witnessed HTDS share values dwindle down to next to nothing. Our goal is to reverse that trend and we believe we are well under way. We have received a number of inquiries about an open Regulation D financing and filing we did. HTDS is a medical company engaged in both RD and vaccine distribution as its core business. Over the next several weeks and months we will be issuing many updates as to what progress the company made. By that we mean, how this financing was used, what equipment was acquired, contracts signed and what assets were acquired, and more importantly the forward strides we made as a company. Our days of being under duress and in peril are well behind us now.
Today, in less than a year we have two very vibrant companies in HTDS. We are focused, determined and the two companies are working hard and there is great synergy and sync between us all. The Mellow Hope division generates revenues and steady cash flows that a business is judged upon, and generally valuated. Slavica Bio Chem on the other hand is a company whose research and development can have astronomical growth impact on our whole organization, and our share price, which by all accounts I can safely say continues to be very undervalued"
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc. 's control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact ; For any corporate matters, please contact , http://www.htdsmedical.com/
DATASOURCE: Hard to Treat Diseases
CONTACT: For medical and scientific dialogue inquiry only, please contact
-------------------- Please buy responsibly. Do not take my word on any stock. Do your own research. Thanks & good luck! Posts: 439 | From: USA | Registered: Jul 2009
| IP: Logged |
posted
Hard to Treat Diseases, Inc. (HTDS) Experiments with Hyperbaric Oxygenation (HBO) Traumatic Brain Injury
BELGRADE, Serbia, Aug. 3 /PRNewswire-FirstCall/ -- Hard to Treat Diseases, Inc. (HTDS:PK), http://www.htdsmedical.com/ announced that researchers in its Slavica BioChem division have reported results on experiments in which the potential beneficial effects of Hyperbaric oxygenation (HBO) after traumatic brain injury have been explored. These experiments were conducted in collaboration with doctors from the Hyperbaric Medical Center, School of Medicine, University of Belgrade, Serbia.
Hyperbaric oxygen (HBO) has been used as a primary or adjunctive therapy over the last 50 years with controversial results, both in experimental and clinical studies. However, the mechanisms underlying the neuroprotective vs. neurodegenerative effects of HBO treatment are still uncertain.
The results of the research group revealed that repetitive HBO treatments, which started 1 hour after traumatic brain injury significantly, reduced axonal loss and neuronal degeneration, suggesting that HBO was able to attenuate the effects of brain damage by reducing the progression of neuronal injury.
These data indicate that HBO-induced prevention of neurodegeneration might be beneficial in improvement of neurological outcome after traumatic brain injury.
Dr. Sanja Pekovic, Chief Project Scientist, Chief Strategy Officer said (sic) "The experiments were performed on rats, but since we haven't hyperbaric chambers, HBO treatments were performed at the Hyperbaric Medical Center. These data for the first time showed (all was visualized using immunohistochemical technique and specific antibodies to neuronal markers) that HBO prevent axonal loss and neuronal degeneration, since data concerning brain injury are lacking and are controversial. "
Our Washington Poster will be posted on Pink Sheets Supplemental Info Filing as a pdf.
The results were presented by Professor Mirjana Stojiljkovic. (Professor Stojiljkovic is in the process of becoming HTDS Medical Advisor - Officer of the company). In a summary, Poster presentation was available for review by attendees at the 38th Annual Meeting of Society for Neuroscience's (SfN) http://www.sfn.org/am2008/ held Nov. 15 to 19, 2008 in Washington, DC, USA. Professor Stojiljkovic reported that poster attracted numerous scientists and medical doctors, and for close to 4 hours discussion on this topic continued. Each year SfN provides the premier venue for neuroscientists to share research findings. By attending lectures, symposia, and workshops, meeting attendees experience the most exciting and cutting-edge research the field of neuroscience has to offer. SfN's annual meeting draws diverse attendees from all over the world.
In other company news, along with the Washington poster filing the company expects to be in a position to file its Q2 financial results, and an updated Pink Sheets Adequate Disclosure with a legal opinion shortly and perhaps as early as this week. Mr.Terry Yuan HTDS CEO said " These are exciting times for us at HTDS. There are a lot of moving parts now within HTDS, which are all positive, and which may have more than better than expected results for us as a whole organization. This includes our IP claim and our Q2 financial statements which are currently being translated from Chinese to USA standards, to name a few. As a company we are pleased to acknowledge that our corporate objectives and set targets are being met.
The company will release further updates as they become available.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact ; For any corporate matters, please contact , http://www.htdsmedical.com/
DATASOURCE: Hard to Treat Diseases
CONTACT: For medical and scientific dialogue inquiry only, please
contact ; For any corporate matters, please contact
-------------------- Please buy responsibly. Do not take my word on any stock. Do your own research. Thanks & good luck! Posts: 439 | From: USA | Registered: Jul 2009
| IP: Logged |
posted
Hard To Treat Diseases (HTDS) Chile Flu Vaccine Tender
SHENZHEN, China, Aug. 7 /PRNewswire-FirstCall/ -- Hard to Treat Diseases, Inc. (HTDS:PK), (http://www.htdsmedical.com/) subsidiary, Shenzhen Mellow Hope Pharm Industrial Co., Ltd. (Mellow Hope) announced today that the general manager of Mellow Hope paid a visit to Chile, in regards to a significant new business development opportunity related to Mellow Hope's MedVac flu vaccine products. The company intends to participate in a formal tender process to supply a couple separate orders to a couple separate and unrelated entities in Chile.
The company is pleased to report that the company has made a significant progress to secure these couple of interests in Chile. Mellow Hope is tendering between 2,000,000 to 5,000,000 doses of Flu vaccine, for the Chilean market.
Mr. Eric Yuan, Spokesperson for the company, said, "The reason this announcement is being made is three fold. Firstly, to keep our followers and shareholders advised of our daily and ongoing business activities. Secondly certain Mellow Hope filings with the Chilean authorities in regards to the tender process will be made public shortly. Although available in Spanish only, the Company felt that shareholders should be advised directly, in order to avoid any distortions or rumors should news of these filings leak out through other channels. Finally, should the bid submission be successful, this may very well be the largest single order the company will fulfill to date, and would represent a material business development of interest to our shareholders."
This is an important update to our followers. The company will release further updates as they become available, and will refer back to this news release periodically to avoid any confusion, due to the fact that there are multiple pending tenders in Chile.
In other Company news, the company intends to release its Q2 financials on or before August 15th due date, shortly followed by its IP position developments, and some positive strides made in that regard. The documents are currently being translated from Chinese to North American standards. The company is responding to its shareholders requests that the information currently displayed on Pink Sheets be updated. This update will be processed over the weekend. The company expects Pink Sheets to display the update(s) shortly in accordance with their verification policies, shortly thereafter.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
Disclaimer
This is not an offer to buy or sell securities in any jurisdiction. This communication is for informational purposes only. This third party publication is not prepared or approved by MMG (Mina Mar Group) and therefore, may not meet research disclosure requirements applicable to MMG. The contents herein may be subject to copyright laws and any dissemination in whole or in part electronically or otherwise may not be shared with others without the author's prior written consent, which consent can unreasonably be withheld. We do not give legal or security trading or accounting advice of any kind. We are not a licensed broker dealer and do not claim to be. We make no representations as to the suitability of any transaction at any time. The opinions, estimates and projections contained in the publication are those of the author as of the date indicated and are subject to change without notice. MMG makes no representation or warranty, express or implied, in respect thereof, takes no responsibility for any errors or omissions which may be contained therein and accepts no liability whatsoever for any loss arising from any use of or reliance on the report or its contents. MMG its affiliates and/or their respective officers, directors, independent contractors or employees may from time to time acquire, hold or sell securities of issuers mentioned in the publication, related securities, or options, futures or other derivative instruments based thereon. MMG may act as financial advisor and/or consultant for certain of the issuers mentioned therein and may receive remuneration for same. MMG or its affiliates may have consulting arrangements with, or provide other remunerated services to, the issuers mentioned herein. The reader should assume that MMG or its affiliates may have a conflict of interest, and should not rely solely on this publication in evaluating whether or not to buy or sell securities of issuers discussed herein.
CONTACT: For medical and scientific dialogue inquiry only, please contact ; For any corporate matters, please contact , http://www.htdsmedical.com/
DATASOURCE: Hard to Treat Diseases
CONTACT: For medical and scientific dialogue inquiry only, please
contact ; For any corporate matters, please contact
-------------------- Please buy responsibly. Do not take my word on any stock. Do your own research. Thanks & good luck! Posts: 439 | From: USA | Registered: Jul 2009
| IP: Logged |
posted
Hard To Treat Diseases (HTDS) exclusive agent and partner of NCPC
SHENZHEN, China, Aug. 11 /PRNewswire-FirstCall/ -- Hard to Treat Diseases, Inc. (HTDS:PK), (http://www.htdsmedical.com/) subsidiary, Shenzhen Mellow Hope Pharm Industrial Co., Ltd. (Mellow Hope) is pleased to announce that an agreement was reached between Mellow Hope and NCPC.
In accordance with the agreement, Mellow Hope was appointed as the exclusive agent and partner of NCPC for its international marketing of Recombinant Hepatitis B Vaccine (CHO).
MARKET BACKGROUND
With the world's largest population and 17 million newborn babies each year, China is the world's fourth largest vaccine market. In China, vaccines represent a market worth over 3 billion RMB ($3.88 million), and this market is growing at 15% annually, reports Dr. Jianyuan Liu, associate director of National Vaccine and Serum Institute (NVSI) in the study, Advances in Biopharmaceutical Technology in China.1 Today, China has the largest vaccine manufacturing capabilities and capacity in the world. Dr. Liu and his colleagues also predict that China's vaccine market demand will rise to 20% in the next few years. Recent improvements in China's regulatory, market, and technology scenario are creating an optimistic outlook for its vaccine industry.
Large population, many newborns
China's population reached 1.3 billion in 2005 and will approach 1.4 billion in the next decade. The state has managed to control its birth rate to between 1.2% and 1.3%. Each year, approximately 17 million Chinese babies are born and all are suppose to receive vaccination. Based on this number, the following vaccine doses are needed each year for newborn babies:2
Poliomyelitis vaccine 68 million doses Diphtheria-pertussistetanus vaccine 68 million doses Hepatitis B vaccine 51 million doses Measles vaccine 34 million doses BCG vaccine 17 million doses
The aforementioned statistics and data were obtained from the following sources without permission
The HTDS management sees this agent agreement as a great potential boost of its revenue streams in introducing International marketing of Recombinant Hepatitis B Vaccine(CHO) to Mellow Hope's already existing distribution network.
In other company news, the company IP progress, Q2 financials and other corporate business matters are in the process of undergoing final review. These will be filed shortly and followed with an announcement.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact ; For any corporate matters, please contact , http://www.htdsmedical.com/
DATASOURCE: Hard to Treat Diseases
CONTACT: For medical and scientific dialogue inquiry only, please
contact ; For any corporate matters, please contact
-------------------- Please buy responsibly. Do not take my word on any stock. Do your own research. Thanks & good luck! Posts: 439 | From: USA | Registered: Jul 2009
| IP: Logged |
posted
Hard To Treat Diseases (HTDS.PK) Completes IP Ownership Filings With U.S. Patent and Trademark Office
SHENZHEN, China, Aug. 12 /PRNewswire-FirstCall/ -- Hard to Treat Diseases (HTDS.PK) http://www.htdsmedical.com/ - further to the Company news release of July 9, 2009 http://www.pinksheets.com/pink/quote/quote.jsp?symbol=htds today at 10:30AM EST that the Company has completed the necessary filings required to correct the ownership of its intellectual property (IP) rights.
Having performed an extensive audit and investigation on five (5) issued patents, HTDS finds that the Company should have been assigned full ownership of the patents. Filings were made today with the U.S. Patent and Trademark Office that formalize, and secure HTTD's ownership and rights to the patents. http://www.uspto.gov/
In summary, The IP rights are being utilized by a fully reporting OTCBB publicly traded company. As a result of HTDS IP rights, this company has raised substantial monies in equity financing, constructed an operating plant that generates revenue, is in the process of purchasing parcels of property in various States in order to construct additional plants. It also has had numerous industrial bonds approved for several million dollars each.
The issuer for the time being has elected not to name the OTCBB publicly traded company that is utilizing its rights, however HTDS has placed the OTCBB company on formal notice. Notwithstanding, HTDS management is looking towards a mutually amicable resolution of this matter. HTDS is of the opinion that this OTCBB company got off to a great start, primarily because of these patents, which rightfully belong to HTDS. HTDS takes the position that there is no good or valid dispute that these IP rights belong to anyone else but HTDS. The following SEC filing http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=652915 dated June 2, 2000 together with today's filings with the U.S. Patent and Trademark Office http://www.uspto.gov/ are self explanatory and apparent on their face.
The issuer expects a "knee jerk" reaction by the OTCBB Company, including the standard form letter type denials issued by their barristers, a denouncement and a host of other panic stricken immediate type reactions. HTDS management intentions are neither to harm the OTCBB operations nor to destabilize OTCBB shareholders value. Instead, it will seek a harmonious "WIN-WIN" solution. Once the rights are finalized, HTDS is positioning itself to aggressively move the recycling industry to a higher level, with a separate recycling operating division inside HTDS; which should not disrupt HTDS' primary Bio Chem and Vaccine business. In the event the OTCBB utilizing HTDS rights is willing to cooperate, HTDS may very well have found a new partner. HTDS management is also mindful that refusal of this infringement may leave the HTDS management with no other alternative but to attorn these IP rights and to appoint an interim HTDS management to assume the recycling operations.
The management of HTDS is not ruling out any options at this point. Either way, once HTDS assumes control, the management anticipates gross revenue exceeding $250 million within two years.
Resolutions and a decision are expected shortly.
In other company news, Mr Terry Yuan CEO of HTDS said "We are delighted by the recent events taking place at HTDS. We wish to take this opportunity to advise our shareholders, and followers that some of the aforementioned revenue figures of both this release and the one of July 9, 2009 were derived directly from the OTCBB Company SEC Filings, and figures taken from OTCBB Company confidential brochures furnished to its accredited investors. We have in our possession, and we intend to file with the Pink Sheets shortly the USPTO corrective filings, the FedEx delivery and HTDS notice of infringements served upon the OTCBB directors, officers, and its auditors in the event of failed mutually acceptable resolution to the IP rights.
At HTDS and here in China we continue business as usual focusing on daily operations. Our extensive audit and investigation on these five (5) issued patents started months ago. There are many outstanding follow up matters which we intend to fully follow up with such as: CEO message from both operating subsidiaries Slavica Bio Chem in Serbia and Mellow Hope in China, our financial filings due shortly, pending legal opinion on the filed adequate disclosure, update on the slander lawsuit where HTDS is one of several beneficiaries, forward guidance, our pennies plus set targeted share price to name a few. Over the course of time we will be providing all of these updates on a timely basis including new, and pending contracts, and progresses we made so far. This is truly an exciting time to be part of the HTDS organization, and we appreciate all of our shareholders and followers sharing that joy mutually with us"
Additional details and information will be released as they become available, via regular news releases or via Pink Sheets filing service.
Safe Harbor Statement:
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact ; For any corporate matters, please contact , http://www.htdsmedical.com/
DATASOURCE: Hard to Treat Diseases
CONTACT: For medical and scientific dialogue inquiry only, please
contact ; For any corporate matters, please contact
-------------------- Please buy responsibly. Do not take my word on any stock. Do your own research. Thanks & good luck! Posts: 439 | From: USA | Registered: Jul 2009
| IP: Logged |
posted
:::laughing::: I`ve been in and out of this stock half a dozen times or more, this last month.
But I believe I am going to buy in and stay in this time.
This baby is making money nearly every single day.
And oh, just wait until winter!
China`s market alone is HUGE!
-------------------- Please buy responsibly. Do not take my word on any stock. Do your own research. Thanks & good luck! Posts: 439 | From: USA | Registered: Jul 2009
| IP: Logged |
posted
As usual my friends just buy and hold for a bit - the run will come. Already made my big bucks on this one. Going for vacation. Best of luck to all.
-------------------- Please buy responsibly. Do not take my word on any stock. Do your own research. Thanks & good luck! Posts: 439 | From: USA | Registered: Jul 2009
| IP: Logged |
-------------------- Please buy responsibly. Do not take my word on any stock. Do your own research. Thanks & good luck! Posts: 439 | From: USA | Registered: Jul 2009
| IP: Logged |
(HTDS.PK) Scientists present encouraging results for the future of Multiple Sclerosis treatment.
BELGRADE, SERBIA, Aug. 14 /PRNewswire-FirstCall/ -- Hard to Treat Diseases, Inc. (HTDS:PK), http://www.htdsmedical.com/ announced today that there is great progress being made with the experimental findings to aid in the suppression or ultimately the cure of Multiple Sclerosis not only in their lab in Belgrade, but around the world. (See unauthorized news link)
In a recent study posted on Aug. 12, 2009 scientists have reversed the Multiple Sclerosis in mice. The study showed the suppression of the immune cells, forcing remission and reversing the disease in mice.
Multiple Sclerosis attacks the central nervous system. The researchers explained that "The new treatment, called GIFT15, is composed of two proteins, GSM-CSF and interleukin-15, that are fused in the lab. Normally, the individual proteins act to stimulate the immune system, but when they're stuck together, the proteins suppress immune response, the researchers explained. They do this by converting B-cells -- a type of white blood cell normally involved in immune response -- into immune suppressive cells."
Dr. Jacques Galipeau and his collegues of the Jewish General Hospital Lady Davis Institute for Medical Research and McGill University in Montreal, took normal B-cells from mice and sprinkled GIFT-15 on the B-cells and when this was given in a single dose intravenously back to the mice that were ill with Multiple sclerosis not only did the disease go away but no significant side effects were seen in the mice as per the researchers.
Researchers in Belgrade are also making progress via using other methodologies that involve Ribavirin and Tiazofurin. Administration of ribavirin and tiazofurin attenuated proliferation of autoreactive T lymphocytes and their infiltration into the nervous tissue, and thereby prevented myelin destruction. These results are encouraging for the future of MS therapy.
In other company news, The company has received many inquiries from its shareholders and followers visa vie meeting the August 15th Q2 financials filings deadline. Mr. Terry Yuan CEO of HTDS said, "The management has decided to release HTDS consolidated financials today August 14th 2009 shortly after the market closes. The reason for that is twofold.
One, we are very pleased where our share price now sits as of close of business day August 13 2009.We have come a long way from being a sub,sub, penny stock, to a transparent well organized, well capitalized company; together with having the market finally begin to recognize our values, and the work our team is doing in Serbia and here in China. HTDS management's aim is to continue with a good solid pace of adding value to HTDS and our shareholders. Secondly, HTDS management goal is to reward both our long and midterm shareholders, instead of catering to those seeking a daily quick profit. We remind our followers that the Q2 financial numbers, obviously will not reflect the recently announced contracts."
Additional details and information will be released as they become available, via regular news releases or via Pink Sheets filing service.
Safe Harbor Statement:
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact ; For any corporate matters, please contact , http://www.htdsmedical.com/
DATASOURCE: Hard to Treat Diseases
CONTACT: For medical and scientific dialogue inquiry only, please
contact ; For any corporate matters, please contact
-------------------- Please buy responsibly. Do not take my word on any stock. Do your own research. Thanks & good luck! Posts: 439 | From: USA | Registered: Jul 2009
| IP: Logged |
posted
'Explosion' of Swine Flu Cases Predicted By GILLIAN WONG, A
9 HOURS 20 MINUTES AGO: Health News, Swine Flu, World News
(Aug. 21) The global spread of swine flu will endanger more lives as it speeds up in the coming months and governments must boost preparations for a swift response to a coming "explosion" of cases, the World Health Organization said Friday. Many countries could see swine flu cases double every three to four days for several months until peak transmission is reached, once cold weather returns to the northern hemisphere, said WHO's Western Pacific director, Shin Yoo.
"At a certain point, there will seem to be an explosion in case numbers," Shin told a symposium of health officials and experts in Beijing. "It is certain there will be more cases and more deaths."
The WHO says the swine flu virus also known as H1N1 has killed almost 1,800 people worldwide, and has declared a pandemic.
International attention has focused on how the pandemic is progressing in southern hemisphere countries such as Australia where winter and the flu season has started. But it is in developing countries that the accelerated spread of swine flu poses the greatest threat as it places underequipped and underfunded health systems under severe strain, Shin said.
WHO earlier estimated that as many as 2 billion people could become infected over the next two years nearly one-third of the world's population.
Others said Shin's cautionary comments were needed but that they were optimistic the spread would not be that serious.
Ann Moen, an influenza expert with the U.S. Centers for Disease Control and Prevention, said that if current trends continue it is possible that the swine flu pandemic will not be worse than a severe flu season.
"I think the world was preparing for an H5N1 (bird flu) pandemic and we didn't get that. So maybe this is our supreme tabletop exercise, a global sort of practice for something bigger," Moen told The Associated Press.
Health officials and drug makers are considering how to speed up production of a vaccine before the northern hemisphere enters its flu season in coming months. Estimates for when a vaccine will be available range from September to December. Delegates from Bangladesh and Myanmar appealed for help in procuring vaccines or making them more affordable for poorer countries, saying they were left vulnerable while rich nations pre-ordered most of the available stock.
"Developing countries like us, we have to fight this war without vaccines," said Mya Oo, deputy health minister of Myanmar. He urged pharmaceutical companies to consider selling the vaccines to developing countries at just above cost.
WHO's flu chief, Keiji Fukuda, said the agency was working hard on the issue, and noted that two drugmakers had pledged to donate 150 million doses of vaccine to poorer countries by the end of October. He said more research was needed to determine how vaccines will be priced.
"Among the many pandemic response issues, this is probably the most critical issue: how we mobilize the vaccines, how we get them to developing countries," Fukuda said.
WHO has stressed that most cases of swine flu are mild and require no treatment, but the fear is that a rash of new infections could overwhelm hospitals and health authorities, especially in poorer countries.
Shin said governments must quickly educate the public, prepare their health systems to care for severe cases and protect those deemed more vulnerable to prevent unnecessary deaths.
"We only have a short time period to reach the state of preparedness deemed necessary," Shin said. "Communities must be aware before a pandemic strikes as to what they can do to reduce the spread of the virus, and how to obtain early treatment of severe cases."
Pregnant women face a higher risk of complications, and the virus also has more severe effects on people with underlying medical conditions such as asthma, cardiovascular disease, diabetes, autoimmune disorders and diabetes, WHO chief Margaret Chan said in a video address.
The last pandemic the Hong Kong flu of 1968 killed about 1 million people. Ordinary flu kills about 250,000 to 500,000 people each year. Swine flu is also continuing to spread during summer in the northern hemisphere. Normally, flu viruses disappear with warm weather, but swine flu is proving to be resilient.
Copyright 2009 The Associated Press. 2009-08-21 09:03:50
-------------------- Please buy responsibly. Do not take my word on any stock. Do your own research. Thanks & good luck! Posts: 439 | From: USA | Registered: Jul 2009
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Were Up]](graemlins/wereup.gif)
